Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Explore Activities by Sara M. Tolaney

Title
Format
Credit Type
Credits
Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC

Content Format:

Text Module

Credit Type:

AAPA | ABIM MOC | ACPE | AMA | ANCC

Credits:

0.50
Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC

Content Format:

Slideset

Credit Type:

AAPA | ABIM MOC | ACPE | AMA | ANCC

Credits:

0.50
Integration of Novel Antibody–Drug Conjugates in Advanced HER2-Low, Hormone Receptor–Positive, and Triple-Negative Breast Cancer

Content Format:

PDF

Credit Type:

--

Credits:

--
InterACT Oncology Team Training: Improving Clinical Outcomes for Patients With High-Risk HR-Positive/HER2-Negative Early-Stage Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer

Content Format:

Podcast Episodes

Credit Type:

AMA

Credits:

0.75
Sequencing Treatment in HER2-Positive Metastatic Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Pushing the Boundaries of Unresectable or Metastatic HER2-Low Breast Cancer Treatment: New Insights and Innovations

Content Format:

Slideset

Credit Type:

--

Credits:

--
Advances in CDK4/6 Inhibition in EBC: Expert Guidance and Case Challenges for the Multidisciplinary Team

Content Format:

Slideset

Credit Type:

--

Credits:

--
Spectrum of HER2 Expression and Its Clinical Implications in Breast Cancer

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.50
HER2 Expression in Breast Cancer

Content Format:

Slideset

Credit Type:

--

Credits:

--
How I Manage Key Toxicities With Adjuvant CDK4/6 Inhibitors for Early Breast Cancer

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Key Studies in Breast Cancer: Independent Conference Coverage of the 2023 ASCO Annual Meeting

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.00
Conference to Clinic: Expert Analysis of the Top Breast Cancer Abstracts From the 2023 Oncology Meeting in Chicago

Content Format:

Video

Credit Type:

AMA

Credits:

0.50
Conference to Clinic: Breast Cancer

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
An Expert’s Guide to ASCO 2023: Preview of the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
Individualizing Care for Patients With Triple-Negative Breast Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Podcast PearlsIndividualizing Care for Patients With Triple-Negative Breast Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Smarter. Stronger. Together: Optimizing Personalized Triple-Negative Breast Cancer Care for Providers and Patients

Content Format:

Multimedia

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.00
Treating Brain Metastases in HER2-Positive Breast Cancer: Progress at Last!

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Smarter. Stronger. Together: Optimizing Personalized Triple-Negative Breast Cancer Care for Providers and Patients

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Key Studies in Breast, Gynecologic, Renal Cell, Urothelial, Lung, Hepatobiliary, and Skin Cancers: CCO Independent Conference Highlights of the 2022 ESMO Congress

Content Format:

Text Module

Credit Type:

AMA

Credits:

1.25
An Expert’s Guide to ESMO 2022: A Preview of the Top Abstracts

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

1.00
Optimal Utilization of Ki67 Testing in HR-Positive/HER2-Negative Early Breast Cancer: Education and Resources for the Oncology and Pathology Healthcare Teams

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Highlights From the 2021 SABCS Symposium

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

1.00
A Look Ahead to SABCS 2021

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Podcast Pearls

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Content Format:

Multimedia

Credit Type:

AMA

Credits:

0.75
ExpressPointsCDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.50
Update: Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
ExpressPoints:Clinical Decision-Making for Patients With HR+ HER2- Early Breast Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Adjuvant Therapy for Patients With HR+/HER2- EBC at High Risk of Recurrence

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC: Downloadable Slides

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
ExpressPoints: HER2-Positive Breast Cancer: A Guide Through an Evolving Treatment Landscape

Content Format:

Slideset

Credit Type:

--

Credits:

--
Managing Patients With HER2+ Breast Cancer and Brain Metastasis: Slides

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER2 Testing and Treatment Decisions In Breast Cancer: Slides

Content Format:

Slideset

Credit Type:

--

Credits:

--
New Targeted Therapies for HER2-Positive Metastatic Breast Cancer: Downloadable Slides

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Insights Into Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Content Format:

Video

Credit Type:

AMA

Credits:

1.25
ExpressPoints: Sequencing Treatment and Overcoming Resistance in HR-Positive/HER2-Negative ABC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
PI3K/AKT/mTOR Inhibitors and Future Directions in HR+/HER2- Advanced Breast Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Key Updates in the Treatment of HER2-Positive Breast Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
New Insights in Breast Cancer: Independent Conference Coverage of SABCS 2019

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

1.00
New Developments in Chemotherapy-Based Treatment for Breast Cancer: Insights From SABCS 2019

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
A Look Ahead to the 2019 SABCS Meeting

Content Format:

Clinical Thought

Credit Type:

AMA

Credits:

0.25